Canopy’s stock reversed on earnings after seeing a rally sparked by the possibility of marijuana reform in the U.S.

Canopy Growth Q3 sales hit C$74.76 million, surpassing estimates. Medical cannabis revenue rose 16%, while adjusted EBITDA loss improved 61% year-over-year.

Canopy Growth Corporation’s CGC share price has surged by 22.22%, which has investors questioning if this is right time to sell.

Canopy Growth (CGC) delivered earnings and revenue surprises of -58.33% and 12.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Canopy Growth Corporation ("Canopy Growth" or the ... political delays and market volatility have affected cannabis stock. "We keep expecting federal reform, we keep getting promised federal ...

The most recent trading session ended with Canopy Growth Corporation (CGC) standing at $1.97, reflecting a -1.01% shift from the previouse trading day's closing. This move lagged the S&P 500's daily ...

Strong holiday sales drove Storz & Bickel net revenue growth of 19% year-over-year Record quarter for Canada medical cannabis with net revenue increasing 16%; international ...

Not only does Canopy Growth still have a lot of debt remaining, its cash flow from operations continues to be negative. Often, tangible book value can help support a stock price, but this doesn't ...

Aurora Cannabis (NASDAQ: ACB) surged 45% after reporting record earnings, boosting CGC, TLRY, and CRON stocks.